Wall Street brokerages expect Charles River Laboratories International, Inc. (NYSE:CRL) to announce earnings per share of $1.22 for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Charles River Laboratories International’s earnings, with the highest EPS estimate coming in at $1.24 and the lowest estimate coming in at $1.21. Charles River Laboratories International posted earnings per share of $1.18 in the same quarter last year, which indicates a positive year-over-year growth rate of 3.4%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Charles River Laboratories International will report full-year earnings of $5.10 per share for the current fiscal year, with EPS estimates ranging from $5.05 to $5.15. For the next financial year, analysts expect that the business will post earnings of $5.63 per share, with EPS estimates ranging from $5.50 to $5.78. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. During the same period last year, the firm earned $1.20 EPS. The company’s revenue for the quarter was up 8.1% on a year-over-year basis.

A number of brokerages recently weighed in on CRL. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price for the company in a report on Wednesday, July 12th. Jefferies Group LLC restated a “buy” rating and issued a $121.00 price target on shares of Charles River Laboratories International in a research report on Friday, June 30th. BidaskClub downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Robert W. Baird reiterated a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Finally, Barclays PLC reiterated a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Charles River Laboratories International has a consensus rating of “Buy” and an average price target of $98.55.

In other news, Chairman James C. Foster sold 43,154 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total value of $4,315,400.00. Following the completion of the transaction, the chairman now owns 361,178 shares in the company, valued at $36,117,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Davide Molho sold 5,982 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total transaction of $643,364.10. Following the completion of the transaction, the insider now owns 22,714 shares of the company’s stock, valued at approximately $2,442,890.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,982 shares of company stock valued at $7,951,868. Corporate insiders own 2.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Charles River Laboratories International by 0.5% in the second quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock worth $511,893,000 after purchasing an additional 27,217 shares in the last quarter. BlackRock Inc. raised its position in Charles River Laboratories International by 4.6% during the second quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock worth $406,913,000 after acquiring an additional 177,239 shares in the last quarter. FMR LLC raised its position in Charles River Laboratories International by 23.8% during the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after acquiring an additional 591,066 shares in the last quarter. Ariel Investments LLC raised its position in Charles River Laboratories International by 30.7% during the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock worth $185,335,000 after acquiring an additional 483,564 shares in the last quarter. Finally, State Street Corp raised its position in Charles River Laboratories International by 2.3% during the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after acquiring an additional 28,365 shares in the last quarter. Institutional investors own 95.82% of the company’s stock.

Shares of Charles River Laboratories International (CRL) traded up 0.13% on Thursday, hitting $107.67. The company had a trading volume of 178,163 shares. Charles River Laboratories International has a 12 month low of $67.20 and a 12 month high of $109.59. The company has a 50-day moving average of $102.39 and a 200 day moving average of $94.99. The stock has a market cap of $5.12 billion, a PE ratio of 28.37 and a beta of 0.99.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Charles River Laboratories International, Inc. (CRL) Will Post Earnings of $1.22 Per Share” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/14/zacks-analysts-expect-charles-river-laboratories-international-inc-crl-will-post-earnings-of-1-22-per-share.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.